ampicillin + amikacin + cefoxitin

This is a combination of three antibiotics—ampicillin, amikacin, and cefoxitin—used together for the treatment of severe or mixed bacterial infections. Each component has a distinct mechanism of action: - **Ampicillin** is a beta-lactam antibiotic (penicillin class) that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell lysis. - **Amikacin** is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting protein synthesis and causing misreading of mRNA in susceptible bacteria. - **Cefoxitin** is a second-generation cephamycin (cephalosporin) antibiotic that also inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. It has broad-spectrum activity against both Gram-positive and Gram-negative bacteria[1][4][5][7]. This combination may be used empirically for serious hospital-acquired infections or polymicrobial infections where broad coverage—including resistant Gram-negative organisms and anaerobes—is required. The use of multiple agents can provide synergistic effects but also increases the risk for toxicity (notably nephrotoxicity with aminoglycosides like amikacin)[3]. No unique brand name exists for this specific triple combination; it would be prepared as needed in clinical settings.